{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:48:21Z","timestamp":1769186901733,"version":"3.49.0"},"reference-count":65,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Relapsed or refractory follicular lymphoma (rrFL) remains difficult to treat in elderly or frail patients who cannot tolerate standard-dose immuno-chemotherapy as well as novel therapies. Metronomic chemotherapy (mCHEMO) may offer sustained antitumor activity with reduced toxicity. This study assessed the clinical activity and safety of R-DEVEC or R-DEVEC-light in rrFL patients following lenalidomide discontinuation or ineligibility. Methods: Data from the ReLLi Lymphoma Registry (2013\u20132025) were retrospectively analyzed. Eligible patients had rrFL after \u22651 prior therapy and initiated mCHEMO at least six months before data cutoff. Thirteen patients received DEVEC or the etoposide-free DEVEC-light regimen; all but one also received rituximab. Responders received maintenance vinorelbine, low-dose prednisone, and rituximab, followed by vinorelbine-only maintenance until progression or intolerance. Responses were assessed by CT after cycle two and PET\/CT at completion of six induction cycles. Results: median age was 77 years (range 58\u201392); most patients were frail and had advanced disease. At the end of induction, 84% achieved remission (46% CR, 38% PR), with three PR converting to CR during maintenance. After a median follow-up of 27 months, the PFS was 42% (95CI 15\u201369%) and the OS 73% (95CI 47\u2013100%). A transformation occurred in one patient; the main toxicity was grade 3 neutropenia (31%). DEVEC-light showed improved tolerability versus full DEVEC, with manageable infections and rare discontinuations. Conclusions: Metronomic R-DEVEC-light is a feasible and effective disease-controlling strategy for frail, heavily pretreated rrFL patients who do not tolerate lenalidomide and are excluded from modern therapies. This schedule warrants further prospective evaluation and exploration in combination with targeted agents.<\/jats:p>","DOI":"10.3390\/cancers18020347","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:58:40Z","timestamp":1769180320000},"page":"347","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed\/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Sabrina","family":"Pelliccia","sequence":"first","affiliation":[{"name":"Haematology Unit, Azienda Ospedaliera Universitaria Sant\u2019Andrea, 00189 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-2066","authenticated-orcid":false,"given":"Marta","family":"Banchi","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, School of Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3797-0741","authenticated-orcid":false,"given":"Lucrezia","family":"De Marchi","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-9706","authenticated-orcid":false,"given":"Emanuele","family":"Cencini","sequence":"additional","affiliation":[{"name":"Haematology Unit, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Seimonte","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2603-9715","authenticated-orcid":false,"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Haematology Unit, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3514-7980","authenticated-orcid":false,"given":"Andrea","family":"Nunzi","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Destefano","sequence":"additional","affiliation":[{"name":"Clinical Pathology, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-9141","authenticated-orcid":false,"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, School of Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-8459","authenticated-orcid":false,"given":"Maria Christina","family":"Cox","sequence":"additional","affiliation":[{"name":"Hematology Unit, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular Lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40164-024-00551-1","article-title":"Current and Future Therapies for Follicular Lymphoma","volume":"13","author":"Zinzani","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide plus Rituximab versus Placebo plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bjh.17045","article-title":"Prognostic Value of POD24 Validation in Follicular Lymphoma Patients Initially Treated with Chemotherapy-Free Regimens in a Pooled Analysis of Three Randomized Trials of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"192","author":"Moccia","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","article-title":"Transformed Follicular Lymphoma","volume":"97","author":"Fischer","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood-2018-05-853499","article-title":"An Open-Label Phase 1b Study of Obinutuzumab plus Lenalidomide in Relapsed\/Refractory Follicular B-Cell Lymphoma","volume":"132","author":"Morschhauser","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(25)01778-7","article-title":"Tafasitamab, Lenalidomide, and Rituximab in Relapsed or Refractory Follicular Lymphoma (InMIND): A Global, Phase 3, Randomised Controlled Trial","volume":"407","author":"Sehn","year":"2026","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/bjh.70126","article-title":"Towards a Chemo-Free Approach for Follicular Lymphoma","volume":"207","author":"Luminari","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood.2024026018","article-title":"Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?","volume":"146","author":"Casulo","year":"2025","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","article-title":"Pharmacokinetics of Metronomic Chemotherapy: A Neglected but Crucial Aspect","volume":"13","author":"Bocci","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2021.10.018","article-title":"Metronomic Chemotherapy Regimens and Targeted Therapies in Non-Hodgkin Lymphoma: The Best of Two Worlds","volume":"524","author":"Cox","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_15","first-page":"2731","article-title":"Antitumor Effects in Mice of Low-Dose (Metronomic) Cyclophosphamide Administered Continuously through the Drinking Water","volume":"62","author":"Man","year":"2002","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1593\/neo.131910","article-title":"Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression","volume":"16","author":"Chen","year":"2014","journal-title":"Neoplasia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CAD.0000000000000319","article-title":"Cellular and Molecular Effects of Metronomic Vinorelbine and 4-O-Deacetylvinorelbine on Human Umbilical Vein Endothelial Cells","volume":"27","author":"Biziota","year":"2016","journal-title":"Anticancer Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3892\/ijo.2015.3059","article-title":"Metronomic Vinorelbine: Anti-Angiogenic Activity in Vitro in Normoxic and Severe Hypoxic Conditions, and Severe Hypoxia-Induced Resistance to Its Anti-Proliferative Effect with Reversal by Akt Inhibition","volume":"47","author":"Mavroeidis","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2005-04-1422","article-title":"Optimal Biologic Dose of Metronomic Chemotherapy Regimens Is Associated with Maximum Antiangiogenic Activity","volume":"106","author":"Shaked","year":"2005","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11372","DOI":"10.1038\/s41598-025-95476-y","article-title":"Synergistic Activity of Tafasitamab and Metronomic Chemotherapy on Diffuse Large B-Cell Lymphoma through Inhibition of the AKT\/MTOR Signaling Pathway","volume":"15","author":"Banchi","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41416-018-0076-z","article-title":"Vinorelbine, Cyclophosphamide and 5-FU Effects on the Circulating and Intratumoural Landscape of Immune Cells Improve Anti-PD-L1 Efficacy in Preclinical Models of Breast Cancer and Lymphoma","volume":"118","author":"Orecchioni","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/1120009X.2020.1819069","article-title":"Active Metronomic Vinorelbine Schedules Decrease Plasma Interleukin-2 Levels in Mice with Lewis Lung Carcinoma","volume":"33","author":"Orlandi","year":"2020","journal-title":"J. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"769790","DOI":"10.1155\/2014\/769790","article-title":"Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study","volume":"2014","author":"Cazzaniga","year":"2014","journal-title":"Int. J. Breast Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Camerini, A., Puccetti, C., Donati, S., Valsuani, C., Petrella, M.C., Tartarelli, G., Puccinelli, P., and Amoroso, D. (2015). Metronomic Oral Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer: Results of a Phase II Trial (MOVE Trial). BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1354-2"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100051","DOI":"10.1016\/j.esmoop.2021.100051","article-title":"Metronomic Oral Vinorelbine in Previously Untreated Advanced Non-Small-Cell Lung Cancer Patients Unfit for Platinum-Based Chemotherapy: Results of the Randomized Phase II Tempo Lung Trial","volume":"6","author":"Camerini","year":"2021","journal-title":"ESMO Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamaoncol.2023.2150","article-title":"Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial","volume":"9","author":"Munzone","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"216900","DOI":"10.1016\/j.canlet.2024.216900","article-title":"Metronomic Chemotherapy in Hematology: Lessons from Preclinical and Clinical Studies to Build a Solid Rationale for Future Schedules","volume":"591","author":"Banchi","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00280-020-04172-3","article-title":"All-Oral Metronomic DEVEC Schedule in Elderly Patients with Peripheral T Cell Lymphoma","volume":"86","author":"Cox","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s10637-019-00769-5","article-title":"The Metronomic All-Oral DEVEC Is an Effective Schedule in Elderly Patients with Diffuse Large b-Cell Lymphoma","volume":"37","author":"Cox","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjh.15039","article-title":"Aggressive Lymphomas of the Elderly: The DEVEC Metronomic Chemotherapy Schedule Fits the Unfit","volume":"183","author":"Cox","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Bocci, G., Pelliccia, S., Orlandi, P., Caridi, M., Banchi, M., Musuraca, G., Di Napoli, A., Bianchi, M.P., Patti, C., and Anticoli-Borza, P. (2022). Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med., 11, Erratum in J. Clin. Med. 2023, 12, 7053. https:\/\/doi.org\/10.3390\/jcm12227053.","DOI":"10.3390\/jcm12227053"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive Geriatric Assessment Is an Essential Tool to Support Treatment Decisions in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Prospective Multicenter Evaluation in 173 Patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","article-title":"Metronomic Chemotherapy: An Attractive Alternative to Maximum Tolerated Dose Therapy That Can Activate Anti-Tumor Immunity and Minimize Therapeutic Resistance","volume":"358","author":"Kareva","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10637-013-9974-3","article-title":"Preclinical Analysis of Resistance and Cross-Resistance to Low-Dose Metronomic Chemotherapy","volume":"32","author":"Chow","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide Efficacy in Activated B-Cell-like Subtype Diffuse Large B-Cell Lymphoma Is Dependent upon IRF4 and Cereblon Expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ioannou, N., Jain, K., and Ramsay, A.G. (2021). Immunomodulatory Drugs for the Treatment of B Cell Malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168572"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41375-022-01749-0","article-title":"MTOR Inhibition Amplifies the Anti-Lymphoma Effect of PI3K\u03b2\/\u03b4 Blockage in Diffuse Large B-Cell Lymphoma","volume":"37","author":"Xu","year":"2023","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study","volume":"37","author":"Bachy","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study","volume":"36","author":"Cheson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients with Refractory Indolent Non-Hodgkin Lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for Patients with Relapsed or Refractory Follicular Lymphoma: An Open-Label, Single-Arm, Multicentre, Phase 2 Trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1182\/blood-2023-179910","article-title":"Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed\/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-Up","volume":"142","author":"Salles","year":"2023","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A Phase I\/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed\/Refractory Lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin\u2019s Lymphoma and Mantle Cell Lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A Phase 2 Study of Mocetinostat, a Histone Deacetylase Inhibitor, in Relapsed or Refractory Lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/bloodadvances.2021006240","article-title":"Safety and Activity of Pembrolizumab in Combination with Rituximab in Relapsed or Refractory Follicular Lymphoma","volume":"6","author":"Nastoupil","year":"2022","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE NHL-1): A Phase 2 Cohort of a Single-Arm, Multicentre Study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5): A Single-Arm, Multicentre, Phase 2 Trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood.2025029909","article-title":"Fixed-Duration Epcoritamab plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma","volume":"146","author":"Falchi","year":"2025","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, Lenalidomide, and Rituximab versus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1): A Global, Open-Label, Randomised, Phase 3 Trial","volume":"407","author":"Falchi","year":"2025","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab Vedotin or Pinatuzumab Vedotin plus Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Final Results from a Phase 2 Randomised Study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2017009","DOI":"10.4084\/mjhid.2017.009","article-title":"Follicular Lymphoma: The Management of Elderly Patient","volume":"9","author":"Castellino","year":"2017","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1200\/JCO.1988.6.12.1838","article-title":"The Importance of Age in Survival of Patients Treated with Chemotherapy for Aggressive Non-Hodgkin\u2019s Lymphoma","volume":"6","author":"Vose","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","article-title":"A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone","volume":"13","author":"Taskinen","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The Anti-Angiogenic Basis of Metronomic Chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_61","first-page":"1878","article-title":"Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-Resistant Cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: Towards Personalized Chemotherapy?","volume":"11","author":"Pasquier","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1593\/neo.101174","article-title":"Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide","volume":"13","author":"Emmenegger","year":"2011","journal-title":"Neoplasia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.23422","article-title":"Prednisone, Etoposide, Procarbazine, and Cyclophosphamide (PEP-C) Oral Combination Chemotherapy Regimen for Recurring\/Refractory Lymphoma: Low-Dose Metronomic, Multidrug Therapy","volume":"112","author":"Coleman","year":"2008","journal-title":"Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00280-016-3136-1","article-title":"The Metronomic Therapy with Prednisone, Etoposide, and Cyclophosphamide Reduces the Serum Levels of VEGF and Circulating Endothelial Cells and Improves Response Rates and Progression-Free Survival in Patients with Relapsed or Refractory Non-Hodgkin\u2019s Lymphoma","volume":"78","author":"Zeng","year":"2016","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/347\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T15:02:53Z","timestamp":1769180573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":65,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18020347"],"URL":"https:\/\/doi.org\/10.3390\/cancers18020347","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}